Brief: Shattuck Labs Enters Into Strategic Collaboration With Ono Pharma To Generate Bifunctional Fusion Proteins
13/02/2024 11:09
Feb 13 (Reuters) - Shattuck Labs Inc STTK.O :
* SHATTUCK LABS ENTERS INTO STRATEGIC COLLABORATION AND
LICENSE
AGREEMENT WITH ONO PHARMACEUTICAL TO GENERATE BIFUNCTIONAL
FUSION PROTEINS FOR THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY
DISEASES
Source text for Eikon: ID:nGNX9rs9pS
Further company coverage: STTK.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Shattuck Labs
See all newsBrief: Shattuck Labs Announces Phase 2 Clinical Trial Of Sl-325 In Hidradenitis Suppurativa And Appointment Of Shoba Ravichandran, M.D., As Senior Vice President, Clinical Development
Shattuck Labs Inc reports results for the quarter ended June 30 - Earnings Summary
U.S. STOCKS ON THE MOVEX-Abbott, Columbia Financial, Jabil
U.S. STOCKS ON THE MOVEX-Abbott, Columbia Financial, Jabil,
U.S. STOCKS ON THE MOVE-Duke Energy, Sea, Cardinal Health